<DOC>
	<DOCNO>NCT01323972</DOCNO>
	<brief_summary>The purpose study show consistency different lot candidate vaccine ( 257049 ) malaria develop GlaxoSmithKline ( GSK ) Biologicals .</brief_summary>
	<brief_title>Consistency Immunogenicity Non Inferiority GSK Biologicals ' Candidate Malaria Vaccine Lots Children</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . A male female child , include , 5 17 month age time first vaccination . Signed thumbprinted informed consent obtain parent ( ) /LAR ( ) child . Where parent ( ) /LAR ( ) illiterate , consent form countersign witness . Healthy subject establish medical history clinical examination enter study . Subjects receive three document dos hepatitis B vaccine . Same sex twin . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurological disorder seizure . Moderate severe malnutrition screening define weight age Zscore le 2 . Acute disease and/or fever time enrolment Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination medical history . Use drug vaccine approve indication study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration license vaccine foreseen study protocol within 7 day first dose study vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Administration immunoglobulins and/or blood product within 1 month precede first dose study vaccine plan administration study period . Child care . Any finding investigator feel would increase risk adverse outcome participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>5 Months</minimum_age>
	<maximum_age>17 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
</DOC>